Effects of 3-4 diaminopyridine (DAP) in motor neuron diseases

Tulio Bertorini, Hani Rashed, Mitzi Zeno, Elizabeth Tolley, Masanori Igarashi, Yingjun D. Li

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

OBJECTIVE: To study the safety of 3-4 diaminopyridine (DAP) in patients with motor neuron diseases and to examine its efficacy in reducing muscle fatigue and weakness and in improving objective parameters of muscle function. DESIGN: Assessments of safety included a questionnaire of symptoms, clinical examination, blood testing, and electrocardiography at each visit; efficacy was assessed by subjective scores of fatigue and weakness; an Amyotrophic Lateral Sclerosis Functional Rating Scale and functional ability scores, including timed verbal scores; manual muscle testing; grip dynamometry; pulmonary function tests; timed functional tests; and electrophysiological studies. PARTICIPANTS: Thirteen subjects with amyotrophic lateral sclerosis and seven subjects with only a lower motor neuron syndrome. MAIN OUTCOMES: Assess tolerability of DAP and determine if there was symptomatic improvement of muscle fatigue. SECONDARY OUTCOME: To determine the effects of DAP on objective parameters of muscle function. RESULTS: The drug was well tolerated with only four subjects reporting tingling of lips and fingers during the active drug period. The subjective scores for fatigue and weakness showed a mild improvement after 4 weeks on DAP compared with placebo. A significant benefit of DAP was also demonstrated in the timed verbal scores. CONCLUSION: 3-4 DAP appeared to be safe and produced subjective benefit in motor neuron diseases. The drug could be added for symptomatic treatment in these diseases. Larger studies are necessary to demonstrate efficacy.

Original languageEnglish (US)
Pages (from-to)129-137
Number of pages9
JournalJournal of Clinical Neuromuscular Disease
Volume12
Issue number3
DOIs
StatePublished - Mar 1 2011

Fingerprint

Motor Neuron Disease
Muscle Fatigue
Amyotrophic Lateral Sclerosis
Muscles
Fatigue
Pharmaceutical Preparations
Safety
Respiratory Function Tests
Muscle Weakness
Motor Neurons
Hand Strength
Lip
Fingers
Electrocardiography
Placebos
Therapeutics

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

Cite this

Effects of 3-4 diaminopyridine (DAP) in motor neuron diseases. / Bertorini, Tulio; Rashed, Hani; Zeno, Mitzi; Tolley, Elizabeth; Igarashi, Masanori; Li, Yingjun D.

In: Journal of Clinical Neuromuscular Disease, Vol. 12, No. 3, 01.03.2011, p. 129-137.

Research output: Contribution to journalArticle

Bertorini, Tulio ; Rashed, Hani ; Zeno, Mitzi ; Tolley, Elizabeth ; Igarashi, Masanori ; Li, Yingjun D. / Effects of 3-4 diaminopyridine (DAP) in motor neuron diseases. In: Journal of Clinical Neuromuscular Disease. 2011 ; Vol. 12, No. 3. pp. 129-137.
@article{21f95b58e41646979cf1127318aae777,
title = "Effects of 3-4 diaminopyridine (DAP) in motor neuron diseases",
abstract = "OBJECTIVE: To study the safety of 3-4 diaminopyridine (DAP) in patients with motor neuron diseases and to examine its efficacy in reducing muscle fatigue and weakness and in improving objective parameters of muscle function. DESIGN: Assessments of safety included a questionnaire of symptoms, clinical examination, blood testing, and electrocardiography at each visit; efficacy was assessed by subjective scores of fatigue and weakness; an Amyotrophic Lateral Sclerosis Functional Rating Scale and functional ability scores, including timed verbal scores; manual muscle testing; grip dynamometry; pulmonary function tests; timed functional tests; and electrophysiological studies. PARTICIPANTS: Thirteen subjects with amyotrophic lateral sclerosis and seven subjects with only a lower motor neuron syndrome. MAIN OUTCOMES: Assess tolerability of DAP and determine if there was symptomatic improvement of muscle fatigue. SECONDARY OUTCOME: To determine the effects of DAP on objective parameters of muscle function. RESULTS: The drug was well tolerated with only four subjects reporting tingling of lips and fingers during the active drug period. The subjective scores for fatigue and weakness showed a mild improvement after 4 weeks on DAP compared with placebo. A significant benefit of DAP was also demonstrated in the timed verbal scores. CONCLUSION: 3-4 DAP appeared to be safe and produced subjective benefit in motor neuron diseases. The drug could be added for symptomatic treatment in these diseases. Larger studies are necessary to demonstrate efficacy.",
author = "Tulio Bertorini and Hani Rashed and Mitzi Zeno and Elizabeth Tolley and Masanori Igarashi and Li, {Yingjun D.}",
year = "2011",
month = "3",
day = "1",
doi = "10.1097/CND.0b013e3182095b2b",
language = "English (US)",
volume = "12",
pages = "129--137",
journal = "Journal of Clinical Neuromuscular Disease",
issn = "1522-0443",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Effects of 3-4 diaminopyridine (DAP) in motor neuron diseases

AU - Bertorini, Tulio

AU - Rashed, Hani

AU - Zeno, Mitzi

AU - Tolley, Elizabeth

AU - Igarashi, Masanori

AU - Li, Yingjun D.

PY - 2011/3/1

Y1 - 2011/3/1

N2 - OBJECTIVE: To study the safety of 3-4 diaminopyridine (DAP) in patients with motor neuron diseases and to examine its efficacy in reducing muscle fatigue and weakness and in improving objective parameters of muscle function. DESIGN: Assessments of safety included a questionnaire of symptoms, clinical examination, blood testing, and electrocardiography at each visit; efficacy was assessed by subjective scores of fatigue and weakness; an Amyotrophic Lateral Sclerosis Functional Rating Scale and functional ability scores, including timed verbal scores; manual muscle testing; grip dynamometry; pulmonary function tests; timed functional tests; and electrophysiological studies. PARTICIPANTS: Thirteen subjects with amyotrophic lateral sclerosis and seven subjects with only a lower motor neuron syndrome. MAIN OUTCOMES: Assess tolerability of DAP and determine if there was symptomatic improvement of muscle fatigue. SECONDARY OUTCOME: To determine the effects of DAP on objective parameters of muscle function. RESULTS: The drug was well tolerated with only four subjects reporting tingling of lips and fingers during the active drug period. The subjective scores for fatigue and weakness showed a mild improvement after 4 weeks on DAP compared with placebo. A significant benefit of DAP was also demonstrated in the timed verbal scores. CONCLUSION: 3-4 DAP appeared to be safe and produced subjective benefit in motor neuron diseases. The drug could be added for symptomatic treatment in these diseases. Larger studies are necessary to demonstrate efficacy.

AB - OBJECTIVE: To study the safety of 3-4 diaminopyridine (DAP) in patients with motor neuron diseases and to examine its efficacy in reducing muscle fatigue and weakness and in improving objective parameters of muscle function. DESIGN: Assessments of safety included a questionnaire of symptoms, clinical examination, blood testing, and electrocardiography at each visit; efficacy was assessed by subjective scores of fatigue and weakness; an Amyotrophic Lateral Sclerosis Functional Rating Scale and functional ability scores, including timed verbal scores; manual muscle testing; grip dynamometry; pulmonary function tests; timed functional tests; and electrophysiological studies. PARTICIPANTS: Thirteen subjects with amyotrophic lateral sclerosis and seven subjects with only a lower motor neuron syndrome. MAIN OUTCOMES: Assess tolerability of DAP and determine if there was symptomatic improvement of muscle fatigue. SECONDARY OUTCOME: To determine the effects of DAP on objective parameters of muscle function. RESULTS: The drug was well tolerated with only four subjects reporting tingling of lips and fingers during the active drug period. The subjective scores for fatigue and weakness showed a mild improvement after 4 weeks on DAP compared with placebo. A significant benefit of DAP was also demonstrated in the timed verbal scores. CONCLUSION: 3-4 DAP appeared to be safe and produced subjective benefit in motor neuron diseases. The drug could be added for symptomatic treatment in these diseases. Larger studies are necessary to demonstrate efficacy.

UR - http://www.scopus.com/inward/record.url?scp=79952129857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952129857&partnerID=8YFLogxK

U2 - 10.1097/CND.0b013e3182095b2b

DO - 10.1097/CND.0b013e3182095b2b

M3 - Article

VL - 12

SP - 129

EP - 137

JO - Journal of Clinical Neuromuscular Disease

JF - Journal of Clinical Neuromuscular Disease

SN - 1522-0443

IS - 3

ER -